DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $262,285 | +131042.5% | 8,888 | +1.9% | 0.00% | 0.0% |
| Q1 2023 | $200 | -26.7% | 8,724 | -11.5% | 0.00% | 0.0% |
| Q4 2022 | $273 | -99.9% | 9,858 | -16.7% | 0.00% | -50.0% |
| Q3 2022 | $362,000 | +9.7% | 11,834 | +5.4% | 0.00% | 0.0% |
| Q2 2022 | $330,000 | -47.7% | 11,230 | -42.9% | 0.00% | -33.3% |
| Q1 2022 | $631,000 | -13.9% | 19,652 | +19.4% | 0.00% | 0.0% |
| Q4 2021 | $733,000 | -1.6% | 16,458 | +11.2% | 0.00% | -25.0% |
| Q3 2021 | $745,000 | +32.1% | 14,799 | +105.3% | 0.00% | +33.3% |
| Q2 2021 | $564,000 | +126.5% | 7,207 | +64.2% | 0.00% | +50.0% |
| Q1 2021 | $249,000 | +19.1% | 4,390 | +75.6% | 0.00% | 0.0% |
| Q4 2020 | $209,000 | +134.8% | 2,500 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $89,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |